Tue, Jan 27, 2015, 6:24 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

  • mdr0418 mdr0418 Jun 16, 2011 5:16 PM Flag

    Analysts still playing catch up!

    For all those who have been in this stock in the low single digits you know how fun this ride has been as we have moved through each analysts target price like a formula one race car. We are now over 23 pps and Maxim has met with management and stamped a 30 pps target on QCOR. That represents a 25% move in 12 months that anyone would be proud of in their personal portfolio, but not those who really understand this company. I fully agree with the 30/50 poster on hitting Maxim's 30 target in July once the earnings are released and I guess analysts would be fired if they were throwing out target prices that are effectively a double in value. They would prefer continuing to kick the can down the road several times versus sticking their neck out too far in fear of missing the mark.

    Here are the key components to why the share price will continue to soar beyond all analysts projections for some time to come and above most who read this board.

    1. Sales team is just hitting their stride with the new territories and this quarter will truly be the first that have allowed them to get fully acquainted with their new areas selling M/S. Look for pps to beat the 20 cent first call by a good margin which will put all the analysts back to their desks having to rework their estimates higher once again which in turn will raise their price targets.

    2. ACTHAR like any drug hitting a new market that is successful in treating life threatening indications will be a sales tool within itself as the doctors begin to pass along the results in their inner circles thereby assisting our sales force before they shake the doctors hand for the first time.

    3. The drug can not be duplicated with a generic and there are no peers to erode market share. This to powerful as everyone knows that getting anything through FDA these days is a crap shoot and most blockbuster drugs are being chased around by generic's after their 7 year exclusivity runs out and we essentially can not be copied.

    4. On label indications give us growth for at least another 5-7 years with no let up in sight. Bailey will be annoucing another on lable indication on the next conference call and it appears it could be LUPUS which looks to be another large market for Questcor to penetrate.

    5. Diabetes is an every growing problem in this country and it appears this could prove to be the largest market of all that we could go after which is currently off label. Bailey may speak to this indication on the upcoming call as well.

    6. Margins will remain strong as our only additionally costs going forward will be increasing our sales force which are all revenue generating machines. If we do add costs other then sales it could be trials for something off label, but the company will not pull that trigger unless the revenue potential is juicy.

    7. We have one of the best CEO's and management teams in the game and nobody is leaving this team as everyone on the inside knows we are only at the beginning of a long and rewarding journey and they will all be rich on their options going forward.

    Someone on this board promised me golf at pebble beach when the stock hits 50. Suggest you begin looking at a calendar as you will be making reservations sooner then planned.

    LONG AND STRONG QCOR!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Your analyses are always well documented. Congrats.

    • #4 in my post seemed rather obvious when I predicted Lupus and the next indication seems equally as obvious. We are talking out in the future, but the next on label indication following the roll out of Lupus will be Rheumatoid Arthritis.

      The hits just keep on coming!!!!

      Long and Strong QCOR.

    • All you need to know.

    • In 10 working days we will have the Q2-2011 earnings release.

    • Now the good news are coming soon. Only 2 weeks.During the summer time it is always interesting to have good news.

    • Hi-Tech Pharmacal (NASDAQ:HITK - Snapshot Report) ranks first with a gain of 3.62%; Elan (NYSE:ELN - Snapshot Report) ranks second with a gain of 3.01%; and Questcor Pharmaceuticals (NASDAQ:QCOR - Snapshot Report) ranks third with a gain of 2.59%.


      Write to Chip Brian at cbrian@mysmartrend.com

    • Monday, July 11, 2011Upward Wedge Detected: (EXAM), (QCOR), (PML), (NTT), (AFCE)
      Upward wedge patterns have been noticed on July 11 for the stocks ExamWorks Group, Inc, Questcor Pharmaceuticals, Inc, PIMCO Municipal Income Fund II, Nippon Telegraph & Telephone Corp, and AFC Enterprises Inc. The price range of these stocks is getting more narrow as the upward trend continues, thus signally the trend is losing steam. This sends a bearish signal to investors as the upward trend is ending.

      Shares of ExamWorks Group, Inc (EXAM) fell by 3.01% or $-0.79/share to $25.59. In the past year, the shares have traded as low as $15.10 and as high as $26.47. On average, 256079 shares of EXAM exchange hands on a given day and today's volume is recorded at 315301.

      Shares of Questcor Pharmaceuticals, Inc (QCOR) fell by 2.53% or $-0.70/share to $27.01. In the past year, the shares have traded as low as $8.89 and as high as $28.04. On average, 946520 shares of QCOR exchange hands on a given day and today's volume is recorded at 788752.

      Shares of PIMCO Municipal Income Fund II (PML) remained unchanged at $10.69. In the past year, the shares have traded as low as $8.89 and as high as $11.29. On average, 102220 shares of PML exchange hands on a given day and today's volume is recorded at 64956.

      Shares of Nippon Telegraph & Telephone Corp (NTT) fell by 0.83% or $-0.20/share to $23.76. In the past year, the shares have traded as low as $20.66 and as high as $25.18. On average, 409520 shares of NTT exchange hands on a given day and today's volume is recorded at 306037.

      Shares of AFC Enterprises Inc (AFCE) fell by 0.54% or $-0.09/share to $16.61. In the past year, the shares have traded as low as $8.62 and as high as $17.57. On average, 102470 shares of AFCE exchange hands on a given day and today's volume is recorded at 22818.

      • 4 Replies to galaberge
      • Jul 11, 2011 (SmarTrend(R) News Watch via COMTEX) -- Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.

        Hi-Tech Pharmacal (NASDAQ:HITK - Snapshot Report) ranks first with a gain of 3.62%; Elan (NYSE:ELN - Snapshot Report) ranks second with a gain of 3.01%; and Questcor Pharmaceuticals (NASDAQ:QCOR - Snapshot Report) ranks third with a gain of 2.59%.

        Depomed (NASDAQ:DEPO - Analyst Report) follows with a gain of 1.27% and Jazz Pharmaceuticals (NASDAQ:JAZZ - Snapshot Report) rounds out the top five with a gain of 1.14%.

        SmarTrend currently has shares of Elan in an Uptrend and issued the Uptrend alert on January 05, 2011 at $6.15. The stock has risen 95% since the Uptrend alert was issued.

        Write to Chip Brian at cbrian@mysmartrend.com

      • Relatively good performance detected in shares of hi-tech pharmacal in the pharmaceuticals industry (hitk, eln, qcor, depo, jazz)

      • None of this is pretty. None of it solves the underlying problems. Not long ago, it seemed like the worst of all options. But if the choice comes down to default vs. short-term patch, let's take the patch. To get there, all parties -- Republicans, Democrats and Obama -- must break loose from their corners.

        The opinions expressed in this commentary are solely those of David Gergen.

      • The debt crisis is pulling Wall Street down.

    • Here is why N/S is a BIG market for ACHTAR of QCOR only in USA:

      Link:http://www.cureresearch.com/n/nephrotic_syndrome/stats.htm


      Death and mortality statistics for Nephrotic syndrome:
      Death statistics for Nephrotic syndrome: The following are statistics from various sources about deaths and Nephrotic syndrome:
      •39,480 people died from nephritis, nephrotic syndrome and nephrosis each year in the US 2001 (Deaths: Final Data for 2001, NCHS, CDC)
      •13.9 people per 100,000 population died from nephritis, nephrotic syndrome and nephrosis each year in the US 2001 (Deaths: Final Data for 2001, NCHS, CDC)
      •Kidney disease was ranked the ninth leading cause of death in the US 2001 (Deaths: Final Data for 2001, NCHS, CDC)
      Read more at http://www.cureresearch.com/n/nephrotic_syndrome/stats.htm?ktrack=kcplink

      Only this potential is $8 BILLION ! So think about it.

    • People are doing their due diligence and they see the very high potential of QCOR especially in these troubled times. So QCOR will be a very good buy up to over $100/share based on the very special and UNIQUE Achtar. $ 10 billion potential revenues.

    • Jul 06, 2011 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR - Snapshot Report) on March 30, 2011 at $14.51. In approximately 3 months, Questcor Pharmaceuticals has returned 84% as of today's recent price of $26.69.

      In the past 52 weeks, shares of Questcor Pharmaceuticals have traded between a low of $8.89 and a high of $27.24 and are now at $26.69, which is 200% above that low price.

      Questcor Pharmaceuticals is currently above its 50-day moving average of $22.30 and above its 200-day moving average of $15.98. Look for these moving averages to climb to confirm the company's upward momentum.

      In the last five trading sessions, the 50-day MA has climbed 1.31% while the 200-day MA has risen 1.03%.

      SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Questcor Pharmaceuticals shares.

      Write to Chip Brian at cbrian@mysmartrend.com

    • View More Messages
 
QCOR
93.600.00(0.00%)Aug 14 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.